Interim report Q3 2021
"The third quarter was another productive period for SynAct Pharma, both from an R&D perspective but also in terms of preparing the company for the intense work ahead and ensuring SynAct is set to take advantage of future opportunities," said Jeppe Øvlesen, CEO.July - September · Net sales during the period amounted to 0 (0) TSEK. · Loss before tax amounted to -20,676 (-9,195) TSEK. · Earnings per share amounted to -0.70 (-0.87) SEK. · Cash flow from operating activities amounted to -18,250 (-8,882) TSEK. · Cash flow from financing activities amounted to 0 (30,806) TSEK.